Table 4 Patient charateristics according to BCR–ABL subtype in patients with Ph+ALL who received HSCT in their first CR following imatinib-based therapy
Minor BCR–ABL (%) | Major BCR–ABL (%) | P | |
|---|---|---|---|
No. of transplantations | 42 | 18 | |
Median days from diagnosis to HSCT (range) | 149 (84–322) | 193 (67–512) | 0.090 |
Conditioning regimen | 0.658 | ||
Myeloablative | 37 (88) | 17 (94) | |
Reduced intensity | 5 (12) | 1 (6) | |
MRD status before HSCT (3 subjects unknown) | 1.000 | ||
Positive | 13 (32) | 5 (29) | |
Negative | 27 (68) | 12 (70) | |
HCT-CI (7 subjects unknown) | 0.400 | ||
0 | 24 (67) | 12 (70) | |
1 | 8 (22) | 5 (30) | |
2– | 4 (11) | ||
Cause of death | |||
Leukemia relapse | 4 (10) | 2 (11) | 1.000 |
Trasnplant related | 5 (12) | 8 (44) | 0.013 |
Graft failure | 1 (2) | 4 (22) | |
Infection | 1 (2) | 2 (11) | |
cGVHD | 1 (2) | 1 (5) | |
BO | 2 (5) | ||
Others | 1 (5) |
